Invention Grant
- Patent Title: T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
-
Application No.: US16769111Application Date: 2018-12-04
-
Publication No.: US11944644B2Publication Date: 2024-04-02
- Inventor: Zelig Eshhar , Tova Waks , Anat Globerson Levin , Moran Rawet Slobodkin
- Applicant: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER , YEDA RESEARCH AND DEVELOPMENT CO. LTD.
- Applicant Address: IL Tel Aviv
- Assignee: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER,YEDA RESEARCH AND DEVELOPMENT CO. LTD
- Current Assignee: THE MEDICAL RESEARCH INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER,YEDA RESEARCH AND DEVELOPMENT CO. LTD
- Current Assignee Address: IL Tel Aviv; IL Rehovot
- Agency: Dorsey & Whitney LLP
- International Application: PCT/IL2018/051325 2018.12.04
- International Announcement: WO2019/111249A 2019.06.13
- Date entered country: 2020-06-02
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K35/17 ; A61K39/395 ; A61P35/00 ; C07K16/28 ; C07K16/30 ; C12N5/0783 ; C12N5/10 ; C12N15/63
Abstract:
The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.
Information query
